Drug intelligence / Profile preview

CAL005

Development stage: Preclinical
Lead developer: Calgent Biotechnology
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CAL005 is a humanized VHH nanobody (single-domain antibody) developed by Calgent Biotechnology. It is designed to target ELR+ CXC chemokines and the CXCR2 receptor. By blocking these targets, CAL005 inhibits the recruitment and activation of neutrophils, which are key drivers of tissue damage in various inflammatory conditions. The drug is currently being developed for the treatment of inflammatory bowel disease (IBD) and other neutrophil-mediated inflammatory diseases.

Targets

IL8 (C-X-C Motif Chemokine Ligand 8)

Beyond the preview

Go deeper on CAL005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAL005.

Explore the full profile